3 days Ago By ABMN Staff
PROCEPT BioRobotics ( NASDAQ:PRCT – Get Free Report ) is expected to post its quarterly earnings results before the market opens on Thursday, April 24th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.49) per share for the quarter.
Persons interested in participating in the company’s conference call can do so using this link . PROCEPT BioRobotics ( NASDAQ:PRCT – Get Free Report ) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.
35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01).
PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%.
The business had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million.
On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year. PROCEPT BioRobotics Stock Down 0.2 % PROCEPT BioRobotics stock opened at $52.
81 on Thursday. The firm has a market capitalization of $2.89 billion, a P/E ratio of -27.
08 and a beta of 1.09. The stock’s fifty day simple moving average is $60.
08 and its 200-day simple moving average is $75.17. PROCEPT BioRobotics has a twelve month low of $47.
04 and a twelve month high of $103.81. The company has a current ratio of 6.
02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.
Wall Street Analysts Forecast Growth Get Our Latest Stock Analysis on PRCT Insider Activity In related news, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.
98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at $6,161,966.46.
This represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink .
Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.
50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20.
The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here .
In the last 90 days, insiders have sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is currently owned by insiders.
About PROCEPT BioRobotics ( Get Free Report ) PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). Featured Articles Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.
com's FREE daily email newsletter ..
